Gan Wen-Juan, Wang Jing-Ru, Zhu Xiao-Li, He Xiao-Shun, Guo Peng-Da, Zhang Shen, Li Xiu-Ming, Li Jian-Ming, Wu Hua
Pathology Center and Department of Pathology, Soochow University, Suzhou, 215123, China.
The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
J Exp Clin Cancer Res. 2016 Oct 19;35(1):164. doi: 10.1186/s13046-016-0441-9.
Aberrant expression of Retinoic acid receptor γ (RARγ) is implicated in cancer development. Our previous study identified that RARγ functions as a tumor promoter to drive hepatocellular carcinoma (HCC) growth. However, its contribution to HCC invasion and metastasis remains unclear.
RARγ expression in clinical HCC samples was detected by western blot and immunohistochemistry. The relationship between RARγ expression levels and the clinical characteristics were evaluated. HCC cell line MHCC-97H were stably knocked down RARγ using a lentivirus vector-based shRNA technique. The cells were analyzed by migration and invasion assays, and injected into nude mice to assess tumor metastasis. E-cadherin expression regulated by RARγ was examined by qPCR, western blot and immunofluorescence staining.
The expression of RARγ is significantly upregulated in human HCC tissues. Moreover, its expression positively correlates with tumor size, distant metastasis and TNM stage, and negatively correlates with length of survival of HCC patients. Knockdown of RARγ markedly inhibits HCC cell invasion and metastasis both in vitro and in vivo. Mechanistic investigations reveal that RARγ functions through regulation of NF-κB-mediated E-cadherin downregulation to promote HCC invasion and metastasis. Notably, RARγ expression status negatively correlates with E-cadherin expression in HCC cell lines and clinical HCC samples.
These findings demonstrate that RARγ could promote HCC invasion and metastasis by regulating E-cadherin reduction, and implicate new strategies to aggressively treat HCC through targeting RARγ/E-cadherin signaling axis.
维甲酸受体γ(RARγ)的异常表达与癌症发展有关。我们之前的研究发现RARγ作为肿瘤促进因子驱动肝细胞癌(HCC)生长。然而,其对HCC侵袭和转移的作用仍不清楚。
通过蛋白质免疫印迹法和免疫组织化学检测临床HCC样本中RARγ的表达。评估RARγ表达水平与临床特征之间的关系。使用基于慢病毒载体的短发夹RNA(shRNA)技术稳定敲低HCC细胞系MHCC-97H中的RARγ。通过迁移和侵袭实验分析细胞,并将其注射到裸鼠体内以评估肿瘤转移。通过定量聚合酶链反应(qPCR)、蛋白质免疫印迹法和免疫荧光染色检测受RARγ调节的E-钙黏蛋白的表达。
RARγ在人HCC组织中的表达显著上调。此外,其表达与肿瘤大小、远处转移和TNM分期呈正相关,与HCC患者的生存时间呈负相关。敲低RARγ在体外和体内均显著抑制HCC细胞的侵袭和转移。机制研究表明,RARγ通过调节核因子κB(NF-κB)介导的E-钙黏蛋白下调发挥作用,从而促进HCC的侵袭和转移。值得注意的是,在HCC细胞系和临床HCC样本中,RARγ的表达状态与E-钙黏蛋白的表达呈负相关。
这些发现表明,RARγ可通过调节E-钙黏蛋白减少促进HCC的侵袭和转移,并提示通过靶向RARγ/E-钙黏蛋白信号轴积极治疗HCC的新策略。